摘要
目的:分析索拉非尼(Sorafenib)获得性耐药人肝癌QGY7702细胞株(QGY7702/Sorafenib)的生物学特性及益气化瘀解毒方对其的干预作用。方法:培养Sorafenib获得性耐药人肝癌QGY7702细胞株,观察该细胞的形态及生长规律,利用CCK-8法分析暴露前后细胞的增殖和药物对细胞毒性的差异,流式细胞术检测耐药细胞的生长周期及凋亡率,划痕实验检测耐药细胞株的迁移能力。结果:Sorafenib获得性耐药人肝癌QGY7702细胞株的耐药性成立,对Sorafenib的耐药性是亲代细胞的2.5倍,与类圆形QGY7702细胞比较,形态转变为梭形或多边形,生长缓慢,对Sorafenib的敏感性降低,凋亡率下降,迁移力增强(P<0.05);益气化瘀解毒方干预后可缩短耐药细胞周期,提高耐药细胞的凋亡率及死亡率,降低耐药细胞的迁移能力(P<0.05)。结论:靶向药物Sorafenib可诱导人肝癌QGY7702细胞耐药并引起耐药细胞的生物学性状改变,益气化瘀解毒方可拮抗Sorafenib耐药。
Objective:To analyze the biological characteristics of Sorafenib-acquired human hepatoma QGY7702 cell line(QGY7702/Sorafenib)and the intervention effect of Yiqi Huayu Jiedu Prescription.Methods:Sorafenib acquired human hepatoma cell line QGY7702 was cultured,and the morphology and growth of the cells were observed.CCK-8 method was used to analyze the proliferation of cells and the cytotoxicity of drugs before and after exposure.Flow cytometry was used to detect drug-resistant cells.The growth cycle and apoptosis rate,scratch test to detect the migration ability of drug-resistant cell lines.Results:The drug resistance of Sorafenib acquired human hepatoma QGY7702 cell line was established,and the resistance to Sorafenib was 2.5 times that of the parental cells.Compared with the round-shaped QGY7702 cells,the morphology changed to fusiform or polygonal,and the growth was slow.The sensitivity to Sorafenib decreased,the apoptotic rate decreased,and the migration ability increased(P<0.05).The intervention of Yiqi Huayu Jiedu Decoction accelerated the drug-resistant cell cycle and increased the'apoptosis rate and mortality of drug-resistant cells.Reduce the migration ability of drug-resistant cells(P<0.05).Conclusion:The targeted drug Sorafenib can induce the drug resistance of human liver cancer QGY7702 cells and cause the biological characteristics of drug-resistant cells.Yiqi Huayu Jiedu Prescription can antagonize Sorafenib resistance.
作者
王亚琪
郜文辉
曾普华
WANG Yaqi;GAO Wenhui;ZENG Puhua(Hunan University of Chinese Medicine,Changsha Hunan China 410208)
出处
《中医学报》
CAS
2019年第10期2153-2157,共5页
Acta Chinese Medicine
基金
国家自然科学基金项目(81603603)
湖南省科技计划项目(2016SK2051)
湖南省教育厅优秀青年项目(14B135)
湖南省中医药管理局重点项目(201803)
